Viking Therapeutics, Inc.
About Viking Therapeutics, Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$359.6M
- Total assets
- $715.7M
- Market cap
- $3.3B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $393.3M
- Operating income
- -$393.3M
- Income tax
- $1.0K
- Net income
- -$359.6M
- EPS (basic)
- $-3.19
- EPS (diluted)
- $-3.19
Balance sheet
- Total assets
- $715.7M
- Current assets
- $715.6M
- Total liabilities
- $76.7M
- Current liabilities
- $76.7M
- Shareholders’ equity
- $639.1M
Cash flow
- Operating cash flow
- -$278.7M
- Investing cash flow
- $341.4M
- Financing cash flow
- $76.4M
- Net cash flow
- $139.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.3B
- EPS (diluted)
- $-3.19
- Shares outstanding
- 119.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 29, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $359.6M in FY2025.
- Trading 34% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Viking Therapeutics, Inc..
Write a review
News about Viking Therapeutics, Inc.
News & sentiment via Polygon.io
